New in-vitro study provides insight: Echinaforce demonstrates in-vitro activity against prevalent viral infections

Cold and flu season is upon us and this year we have added dangers of SARS-CoV-2 (Covid-19).

Cold and Flu

Krista Halton

16 December 2020

A recent in-vitro study, published in the Virology Journal, explored the impact of Echinaforce® against enveloped viruses, including members of the coronavirus family such as MERS, SARS-CoV-1, and common cold HCoV-229E.3

Conducted at the Spiez Laboratory, a high-end facility in Switzerland by independent researchers, cell experiments showed positive preliminary results on anti-viral activity.

While authors conclude that 'Echinaforce®, could be effective as preventative treatment for all CoVs due to their structural similarities',* these results have yet to be confirmed in human clinical trials.

We are continuing our research in this field on a large scale (human) controlled clinical trial and hope to have results as to the effect on humans in the next year.

Now, more than ever, it is imperative to remember that the best form of prevention for viral infections is a strong immune system.

Over the decades, Echinaforce® has undergone more than 30 clinical trials ranging from in-vitro to randomized, double-blind, placebo-controlled and has a long-standing reputation for efficacy and safety.

To protect you and your family, Echinaforce® can be taken daily up to 4 months.4 It works by effectively modulating the immune system to help reduce the inflammatory response of an attacking cold and flu virus and activates the body's antiviral defenses to prevent infection, particularly for those in higher risk categories such as the elderly, children, people under high stress levels or fatigue and smokers.5,6

Echinaforce® is officially approved by Health Canada for the following:

Echinaforce® is clinically shown to help prevent and relieve the symptoms of upper respiratory tract infections (URTI), such as the common cold and the flu. Shortens the duration of URTI. It is also used to support the immune system, especially in times of stress, lack of sleep and for smokers.

It can be taken up to 4 months daily for prevention and there are formulations that are approved for children ages 2+ as well as pregnant and nursing women.

*Disclaimer: This is preliminary research and does not suggest a clinically applicable therapeutic benefit. A.Vogel follows and supports Health Canada guidelines in the battle against COVID-19.

Echinaforce protects

1) Hudson, James, and Selvarani Vimalanathan. "Echinacea—A source of potent antivirals for respiratory virus infections." Pharmaceuticals 4.7 (2011): 1019-1031.
2) Schapowal A., et al. "Echinacea reduces the risk of recurrent respiratory tract infections and complications. a meta-analysis of randomized controlled trials". Advances in Therapy 32.3 (2015): 187-200.
3) Signer, Johanna, et al. "In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2." Virology Journal 17.1 (2020): 1-11.
4) M.Jawad, R.Schoop, A.Suter, P.Klein, R.Eccles: Safety and Efficacy of Echinacea to Prevent Common Cold. Evid Based Complement Alternat Med. 2012;2012:841315
5) Effects of Echinaforce® treatment on ex vivo-stimulated blood cells M.R. Ritchiea,∗, J. Gertschb, P. Kleinc, R. Schoopd2011
6) Echinacea Extract: Bactericidal and Immunomodulatory for Clinically Relevant Pathogens of Respiratory Tract Infections1 S.M. Sharma a, M.Andersonb, S.R.Schoopc, J.B.Hudson2010


A.Vogel Echinaforce® Echinacea Tablets

A.Vogel Echinaforce® Tabs

120 Tabs

$ 19.59

add to basket

Made with 400 mg of Fresh Echinacea tincture per tablet. Prevent colds, get your immune system …
More info